Nuvion (visilizumab) / PDL - LARVOL DELTA

What is the optimal biological therapy for moderate to severe ulcerative colitis: a systematic review and network meta-analysis. (PubMed, Front Pharmacol) - "No significant differences between active interventions were observed when assessing safety outcomes, except for visilizumab...Regarding safety ranking, golimumab 100 mg was the lowest. In this network meta-analysis, infliximab and vedolizumab emerged as the most effective biologics for inducing and maintaining efficacy outcomes for patients with UC. Most drugs were found to be safe and well-tolerated, with ustekinumab and mirikizumab exhibiting particularly favorable safety profiles."

Journal • Retrospective data • Review • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammatory Bowel Disease • Ulcerative Colitis

Novel Drugs in the Treatment of Steroid Refractory Acute Graft Versus Host Disease (ASH 2022) - "A summary of the results is described here.Result s :Denilekin diftitox (Ontak), a recombinant protein composed of IL-2 fused to diphtheria toxin, was studied in a phase 1 trial by Vincent et al...OS at 1 and 2 years was 50% and 38.6%, respectively.Pentostatin, an adenosine deaminase inhibitor, was studied by Meade et al...On an average dose of 5 mg/m2, sirolimus showed a CR of 23% and PR of 33%.Couriel et al., in a phase III trial, 63 patients were randomized and received either methylprednisone (MP) 2mg/kg or infliximab plus MP...reported the results of a phase II trial in which 44 patients were treated with visilizumab with ORR of 32% at day 42.Bordigoni et al. treated 62 patients with daclizumab in a phase II trial with reportef ORR of 68.80% at 44 months follow up.Groth et al...Monoclonal antibodies in particular showed good treatment outcomes with tolerable safety profile. Further studies are required to identify a valuable therapeutic option, SR-aGVHD."

Acute Graft versus Host Disease • Bone Marrow Transplantation • Graft versus Host Disease • Hematological Malignancies • Immunology • Infectious Disease • Oncology • IL2

PD-1 Inhibitor Combined With Azacytidine and Homoharringtonine，Cytarabine, G-CSF for Refractory or Relapsed AML (clinicaltrials.gov) - P3; N=30; Recruiting; Sponsor: The First Affiliated Hospital of Soochow University; Not yet recruiting ➔ Recruiting

Enrollment open • Acute Myelogenous Leukemia • Hematological Malignancies • Leukemia • Oncology

PD-1 Inhibitor Combined With Azacytidine and Homoharringtonine，Cytarabine, G-CSF for Refractory or Relapsed AML (clinicaltrials.gov) - P3; N=30; Not yet recruiting; Sponsor: The First Affiliated Hospital of Soochow University

Clinical • New P3 trial • Acute Myelogenous Leukemia • Hematological Malignancies • Leukemia • Oncology

Renuvion APR Device to Improve the Appearance of Lax Tissue in the Neck and Submental Region (clinicaltrials.gov) - P=N/A; N=82; Recruiting; Sponsor: Apyx Medical; N=52 ➔ 82; Trial completion date: Apr 2021 ➔ Feb 2022; Trial primary completion date: Apr 2021 ➔ Feb 2022

Clinical • Enrollment change • Trial completion date • Trial primary completion date

Renuvion Dermal System for Dermal Resurfacing (clinicaltrials.gov) - P=N/A; N=55; Active, not recruiting; Sponsor: Apyx Medical; Recruiting ➔ Active, not recruiting; Trial completion date: Nov 2020 ➔ May 2021; Trial primary completion date: Oct 2020 ➔ Feb 2021

Clinical • Enrollment closed • Trial completion date • Trial primary completion date

Renuvion Dermal System for Dermal Resurfacing (clinicaltrials.gov) - P=N/A; N=55; Recruiting; Sponsor: Apyx Medical; Trial completion date: May 2021 ➔ Nov 2020; Trial primary completion date: Feb 2021 ➔ Oct 2020

Clinical • Trial completion date • Trial primary completion date

Renuvion Dermal System for Dermal Resurfacing (clinicaltrials.gov) - P=N/A; N=55; Recruiting; Sponsor: Apyx Medical; Trial completion date: Nov 2020 ➔ May 2021; Trial primary completion date: Aug 2020 ➔ Feb 2021

Clinical • Trial completion date • Trial primary completion date

Targeting T cells in inflammatory bowel disease. (PubMed, Pharmacol Res) - "Amongst anti-CD3 antibodies, visilizumab and foralumab did not show clinical efficacy in ulcerative colitis (UC) and Crohn's disease (CD) patients, respectively, whereas otelixizumab has been tested in vitro only. The anti-CD4 BF-5 and cM-T412, and the anti-CD25 basiliximab and daclizumab were not effective in CD and UC patients, respectively...Apart from ustekinumab, all the other drugs targeting T cell-derived cytokines failed. The reinduction of lamina propria T cell apoptosis is a mechanism to modulate T cell survival exploited by cyclosporin A, azathioprine and anti-tumor necrosis factor-α agents, such as infliximab, adalimumab and golimumab. In this article, we review the drugs targeting T cells via surface receptors, via T cell-derived cytokines, via CRAC channels or by inducing apoptosis."

Journal • Review • Crohn's disease • Gastroenterology • Immune Modulation • Immunology • Inflammation • Inflammatory Bowel Disease • Ulcerative Colitis • CD40LG • NKG2D • TNFA

Pulsed and Fractionated Techniques for Helium Plasma Energy Skin Resurfacing. (PubMed, Facial Plast Surg Clin North Am) - "These end results must be balanced with the degree and duration of morbidity, which affect recovery from treatment. Renuvion skin resurfacing protocols include a free hand approach and we describe our preferred approach of pulsing and fractionating the helium plasma resurfacing energy."

Journal • Review • Aesthetic Medicine

Renuvion RF-Helium Plasma for Subdermal Skin Tightening, Facial Contouring and Skin Rejuvenation of the Face and Neck. (PubMed, Facial Plast Surg Aesthet Med) - No abstract available

Journal

A Single-site Postmarket Retrospective Chart Review of Subdermal Coagulation Procedures with Renuvion. (PubMed, Plast Reconstr Surg Glob Open) - "None of the patients required a revision or secondary procedure suggesting 100% of patients had acceptable final outcomes. No device-related adverse events or complications were noted, suggesting that within this data set, Renuvion's unique cool helium plasma technology can safely be used for skin contraction with or without tumescent liposuction or supplemental modalities used to facilitate fat removal that may otherwise contribute to the skin contraction."

Journal • P4 data • Retrospective data

Renuvion/J-Plasma for Subdermal Skin Tightening Facial Contouring and Skin Rejuvenation of the Face and Neck. (PubMed, Facial Plast Surg Clin North Am) - "The tissue surrounding the treatment site remains at much cooler temperatures resulting in rapid cooling of the tissue through conductive heat transfer. Compared to bulk tissue heating devices, this method of action results in effective soft tissue contraction with a lower risk of injury to surrounding tissue."

Journal • Review

Renuvion Dermal System for Dermal Resurfacing (clinicaltrials.gov) - P=N/A; N=55; Recruiting; Sponsor: Apyx Medical

Clinical • New trial